Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women

References

• Bachmann GA, Nevadunsky NS. 2000. Diagnosis and treatment of atrophic vaginitis. American Family Physician 61:3090–3096.
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Amore FF, Ventura B, Bambili E, Spadola S, Cianci A. 2016. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 23:47–54.
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. 2005. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52:S46–S52.
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. 2015. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 18:226–232.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. 2002. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. Journal of Sex & Marital Therapy 28:317–330.
   PubMed Web of Science ®Google Scholar
• Domoney C, Currie H, Panay N, Maamari R, Nappi RE. 2013. The CLOSER survey: impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause International 19:69–76.
   PubMedGoogle Scholar
• Filocamo MT, Serati M, Li Marzi V, Costantini E, Milanesi M, Pietropaolo A, et al. 2014. The Female Sexual Function Index (FSFI): linguistic validation of the Italian version. The Journal of Sexual Medicine 11:447–453.
   PubMed Web of Science ®Google Scholar
• Freedman MA. 2008. Vaginal pH, Estrogen and Genital Atrophy. Menopause Management 17:9–13.
   Google Scholar
• Freedman MA. 2014. Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey. Women's Health 10:445–454.
   PubMedGoogle Scholar
• Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. 2016. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American Journal of Obstetrics and Gynecology 215:704–711.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. 2014. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric: The Journal of the International Menopause Society 17:173–182.
   PubMed Web of Science ®Google Scholar
• Guidozzi F, Thomas C, Smith T, Nappi RE. 2017. CLarifying vaginal atrophy’s impact On SEx and Relationships (CLOSER) survey in South Africa. Climacteric 20:49–54.
   PubMed Web of Science ®Google Scholar
• Huang AJ, Gregorich SE, Kuppermann M, Nakagawa S, Van Den Eeden SK, Brown JS, et al. 2015. Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause 22:144–154.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. 2016. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23:243–256.
   PubMed Web of Science ®Google Scholar
• Latif EZ, Diamond MP. 2013. Arriving at the diagnosis of female sexual dysfunction. Fertility and Sterility 100:898–904.
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. 2008. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15:661–666.
   PubMed Web of Science ®Google Scholar
• Mac Bride MB, Rhodes DJ, Shuster LT. 2010. Vulvovaginal atrophy. Mayo Clinic Proceedings 85:87–94.
   PubMed Web of Science ®Google Scholar
• McCall-Hosenfeld JS, Jaramillo SA, Legault C, Freund KM, Cochrane BB, Manson JE, et al. 2008. Correlates of sexual satisfaction among sexually active postmenopausal women in the Women's Health Initiative-Observational Study. Journal of General Internal Medicine 23:2000–2009.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Biglia N, Cagnacci A, Di Carlo C, Luisi S, Paoletti AM. 2016. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology 32:602–606.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martella S, Rossi M, Tiranini L, Martini E. 2016. Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). Maturitas 94:87–91.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, Simon J. 2013. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. The Journal of Sexual Medicine 10:2232–2241.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. 2010. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67:233–238.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. 2012. Vaginal health: insights, views & attitudes (VIVA) - results from an international survey. Climacteric: The Journal of the International Menopause Society 15:36–44.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Mattsson L-Å, Lachowsky M, Maamari R, Giraldi A. 2013. The CLOSER survey: impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas 75:373–379.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A, et al. 2019. Addressing vulvovaginal atrophy (VVA)/genitourinary syndrome of menopause (GSM) for healthy aging in women. Frontiers in Endocrinology 10:561.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. 2014. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric: The Journal of the International Menopause Society 17:3–9.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. 2016. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric: The Journal of the International Menopause Society 19:188–197.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Particco M, Panay N. 2016. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas 91:81–90.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Seracchioli R, Salvatore S, Cagnacci A, Di Paolantonio T, Busacca M. 2019. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecological Endocrinology 35:453–459.
   PubMed Web of Science ®Google Scholar
• Palacios S, Cancelo MJ, Castelo Branco C, Llaneza P, Molero F, Borrego RS. 2017. Vulvar and vaginal atrophy as viewed by the Spanish REVIVE participants: symptoms, management and treatment perceptions. Climacteric: The Journal of the International Menopause Society 20:55–61.
   PubMed Web of Science ®Google Scholar
• Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N. 2018. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 21:286–286.
   PubMed Web of Science ®Google Scholar
• Palma F, Della Vecchia E, Cagnacci A. 2016. Medical and patient attitude towards vaginal atrophy: the AGATA study. Climacteric: The Journal of the International Menopause Society 19:553–557.
   PubMed Web of Science ®Google Scholar
• Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE. 2019. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 124:55–61.
   PubMed Web of Science ®Google Scholar
• Pandit L, Ouslander JG. 1997. Postmenopausal vaginal atrophy and atrophic vaginitis. The American Journal of the Medical Sciences 314:228–231.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA, Kingsberg SA. 2013. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. International Journal of Women’s Health 5:437–447.
   PubMedGoogle Scholar
• Portman DJ, Gass ML. 2014. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 21:1063–1068.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA, Group OS. 2013. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 20:623–630.
   PubMed Web of Science ®Google Scholar
• Santoro N, Komi J. 2009. Prevalence and impact of vaginal symptoms among postmenopausal women. The Journal of Sexual Medicine 6:2133–2142.
   PubMed Web of Science ®Google Scholar
• Senshio; INN-ospemifene - WC500182775.pdf [online]. 2017. Available from: [Accessed 2017 Mar 4]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002780/WC500182775.pdf.
   Google Scholar
• Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. 2014. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 21:137–142.
   PubMed Web of Science ®Google Scholar
• Smith KB, Pukall CF. 2014. Sexual function, relationship adjustment, and the relational impact of pain in male partners of women with provoked vulvar pain. The Journal of Sexual Medicine 11:1283–1293.
   PubMed Web of Science ®Google Scholar
• Thomas HM, Bryce CL, Ness RB, Hess R. 2011. Dyspareunia is associated with decreased frequency of intercourse in the menopausal transition. Menopause 18:152–157.
   PubMed Web of Science ®Google Scholar
• Wiegel M, Meston C, Rosen R. 2005. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. Journal of Sex & Marital Therapy 31:1–20.
   PubMed Web of Science ®Google Scholar
• Wurz GT, Kao C-J, DeGregorio MW. 2014. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clinical Interventions in Aging 9:1939–1950.
   PubMed Web of Science ®Google Scholar